Covimectin 12 mg

When prescribed for a susceptible parasitic infection, Covimectin 12 mg acts directly against the parasite responsible for the condition. Its established treatment benefits include:

• Treating susceptible intestinal worms

• Reducing microfilariae in onchocerciasis

• Relieving parasite-related itching

• Treating selected mite infestations

• Providing an oral treatment option

• Supporting control of specific parasitic diseases

Successful treatment can reduce symptoms such as itching, skin irritation, abdominal discomfort and diarrhoea caused by the diagnosed parasite. Follow-up tests or repeat treatment are required for some infections.

COVID-19 and cancer research has helped scientists better understand ivermectin’s wider biological effects. These findings have not established a clinical treatment benefit for either condition.

Ivermectin binds to specialised chloride channels found in the nerve and muscle cells of susceptible parasites. This increases the movement of chloride ions into their cells and interrupts normal nerve activity.

The affected parasite becomes paralysed and eventually dies because it can no longer move, feed or remain attached to body tissues. The body can then remove it naturally.

For onchocerciasis, ivermectin mainly reduces young worms called microfilariae. It does not reliably kill the adult worms, which is why monitoring and repeat treatment can be necessary.

COVID-19 research examined possible effects on viral processes, while cancer research has studied cell-growth pathways and immune activity. These experimental mechanisms have not established Covimectin as an antiviral or cancer medicine.

There is no single Covimectin 12 mg dosage suitable for every parasitic infection. Ivermectin dosing is calculated according to body weight and the diagnosed condition.

For intestinal strongyloidiasis, ivermectin is commonly prescribed as a single oral dose of approximately 200 micrograms per kilogram of body weight.

For onchocerciasis, treatment commonly uses a single dose of approximately 150 micrograms per kilogram. Follow-up and repeat treatment are determined by the healthcare professional or treatment programme.

Take the prescribed amount on an empty stomach with water. Follow-up stool tests can be required after strongyloidiasis treatment to confirm that the infection has cleared.

A 12 mg tablet is a product strength and not a universal adult dose. Do not automatically take one complete tablet without confirming the calculated amount.

There is no established Covimectin 12 mg dosage for COVID-19 or cancer. Online protocols and cancer-research schedules should not be copied for self-treatment. Taking repeated or excessive doses can cause serious neurological effects.

Common Side Effects: Covimectin 12 mg can cause nausea, vomiting, diarrhoea, stomach discomfort, dizziness, sleepiness, headache, tiredness, itching, rash or mild swelling. People treated for onchocerciasis can also develop fever, joint pain, swollen lymph nodes and increased itching as the body reacts to dying parasites. Speak to a healthcare professional if these effects persist or become difficult to manage.

Serious Side Effects: Obtain urgent medical attention for severe dizziness, fainting, confusion, difficulty walking, seizures, loss of consciousness, breathing difficulty, facial or throat swelling, severe skin blistering, yellow skin or eyes or unusually low blood pressure. People with heavy Loa loa infection face a rare risk of serious brain-related complications following ivermectin treatment.

Covimectin requires medical assessment before use. Particular caution applies to:

• People allergic to ivermectin

• Pregnant women

• Breastfeeding women

• Children weighing less than 15 kg

• People with suspected Loa loa infection

• People with significant liver disease

• People with serious neurological conditions

• People taking warfarin

• People self-treating COVID-19 or cancer

Tell the healthcare professional about every medicine, supplement and herbal product being used.

Important combinations requiring medical review include:

• Warfarin and other anticoagulants

• Sedatives and sleeping medicines

• Other antiparasitic medicines

• Chemotherapy medicines

• Immunotherapy medicines

• Liver-affecting medicines

• Herbal products and supplements

Rare reports have linked ivermectin taken with warfarin to an increased INR, which can raise the risk of bleeding. Additional blood-clotting tests can therefore be required.

Interaction information for repeated ivermectin use in COVID-19 or cancer protocols remains limited. Do not combine Covimectin with these treatments without a complete medical review.

• Keep Covimectin in its original packaging.

• Store it in a cool and dry place.

• Protect the tablets from light and moisture.

• Follow the temperature stated on the supplied pack.

• Keep the medicine away from children and pets.

• Do not use tablets from damaged packaging.

• Check the batch number and expiry date before use.

• Dispose of expired tablets according to local requirements.